Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study.
暂无分享,去创建一个
[1] Yong-Qing Wang,et al. Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors. , 2016, Current drug metabolism.
[2] S. Tan,et al. Chiral liquid chromatography-mass spectrometry (LC-MS/MS) method development for the detection of salbutamol in urine samples. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[3] Jian Wang,et al. Determination of lansoprazole enantiomers in dog plasma by column-switching liquid chromatography with tandem mass spectrometry and its application to a preclinical pharmacokinetic study. , 2015, Journal of separation science.
[4] D. Svinarov,et al. Critical development by design of a rugged HPLC-MS/MS method for direct determination of ibuprofen enantiomers in human plasma. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[5] Z. Hong,et al. Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. , 2015, Journal of pharmaceutical and biomedical analysis.
[6] Wei Li,et al. Determination of a deuterohemin-peptide conjugate in rat plasma by liquid chromatography-tandem mass spectrometry and application to a preclinical pharmacokinetic study. , 2014, Journal of pharmaceutical and biomedical analysis.
[7] D. Johnson,et al. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium) , 2014, Expert opinion on pharmacotherapy.
[8] C. Nakamura,et al. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes , 2001, European Journal of Clinical Pharmacology.
[9] Xiaoyan Chen,et al. Enantioselective determination of ornidazole in human plasma by liquid chromatography-tandem mass spectrometry on a Chiral-AGP column. , 2013, Journal of pharmaceutical and biomedical analysis.
[10] Kishore Kumar Hotha,et al. Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. , 2012, Biomedical chromatography : BMC.
[11] S. Nudurupati,et al. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg , 2011, Clinical and experimental gastroenterology.
[12] R. Fass,et al. Dexlansoprazole MR – A review , 2011, Annals of medicine.
[13] P. Kole,et al. Recent advances in sample preparation techniques for effective bioanalytical methods. , 2011, Biomedical chromatography : BMC.
[14] Lili Lin,et al. A novel fluorescent enantioselective discrimination of lansoprazole based on a chiral N,N′-dioxide–Sc(III) complex , 2010 .
[15] J. Remon,et al. A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. , 2010, Journal of separation science.
[16] Q. Cass,et al. Two-dimensional chromatography method applied to the enantiomeric determination of lansoprazole in human plasma by direct sample injection. , 2010, Chirality.
[17] R. Cirilli,et al. Development and validation of an enantioselective and chemoselective HPLC method using a Chiralpak IA column to simultaneously quantify (R)-(+)- and (S)-(-)-lansoprazole enantiomers and related impurities. , 2009, Journal of pharmaceutical and biomedical analysis.
[18] A. Wen,et al. Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. , 2009, Current therapeutic research, clinical and experimental.
[19] D. Metz,et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy , 2009, Alimentary pharmacology & therapeutics.
[20] S. Zeng,et al. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? , 2008, World journal of gastroenterology.
[21] A. Cifuentes,et al. Liquid separation techniques coupled with mass spectrometry for chiral analysis of pharmaceuticals compounds and their metabolites in biological fluids. , 2006, Journal of pharmaceutical and biomedical analysis.
[22] N. Yasui-Furukori,et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes , 2004, European Journal of Clinical Pharmacology.
[23] M. Miura,et al. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[24] K. Arimori,et al. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. , 2001, Biological and Pharmaceutical Bulletin.
[25] K. Yasuda,et al. Pharmacokinetics:Pharmacokinetic Differences Between Lansoprazole Enantiomers in Rats , 1998 .